July 20, 2024

Dermatology Diagnostic Devices and Therapeutics Market Size To Cross USD 34.9 Bn By 2030

The global dermatology diagnostic devices and therapeutics market size accounted for US$ 17.65  Bn in 2022 and is projected to reach around USD 34.9 Bn by 2030, growing at a CAGR of 8.89% from 2022 to 2030.

Dermatology Diagnostic Devices and Therapeutics Market Size 2022 To 2030

Report Summary

The global dermatology diagnostic devices and therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the dermatology diagnostic devices and therapeutics market across the globe.

A comprehensive estimate on the dermatology diagnostic devices and therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of dermatology diagnostic devices and therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2409

Dermatology Diagnostic Devices and Therapeutics Market Report Scope 

Report CoverageDetails
Market Size in 2022USD 17.65 Billion
Market Size by 2030USD 34.9 Billion
Growth Rate from 2022 to 2030CAGR of 8.89%
Largest MarketNorth America
Fastest Growing MarketAsia Pacific
Base Year2021
Forecast Period2022 to 2030
Segments Covered
  • By Diagnostic Devices
  • By Application Class
  • By End UseReport Scope of the Dermatology Diagnostic Devices and Therapeutics Market
    Report CoverageDetails
    Market Size in 2022USD 17.65 Billion
    Market Size by 2030USD 34.9 Billion
    Growth Rate from 2022 to 2030CAGR of 8.89%
    Largest MarketNorth America
    Fastest Growing MarketAsia Pacific
    Base Year2021
    Forecast Period2022 to 2030
    Segments Covered
    • By Diagnostic Devices
    • By Application Class
    • By End Use

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized dermatology diagnostic devices and therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  U.S. Digital Therapeutics Market Size To Cross USD 12.09 Bn By 2030

Dermatology Diagnostic Devices and Therapeutics Market Players

The report includes the profiles of key dermatology diagnostic devices and therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Canfield Scientific, Inc.
  • Novartis International AG
  • Valeant Pharmaceuticals International, Inc.
  • gfa-Gevaert N.V.
  • Galderma S.A.
  • Michelson Diagnostics Ltd.
  • Cutera, Inc.
  • Astellas Pharma, Inc.
  • Genentech
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Dino-Lite Europe/IDCP B.V.

Market Segmentation

By Diagnostic Devices

  • Dermatoscopes
  • Microscopes and Trichoscopes
  • Imaging Equipment

By Application Class

  • Diagnostic Devices
    • Skin Cancer Diagnosis
    • Other
  • Treatment Devices
    • Hair Removal
    • Skin Rejuvenation
    • Acne, Psoriasis, and Tattoo Removal
    • Wrinkle Removal and Skin Resurfacing
    • Body Contouring and Fat Removal
    • Cellulite Reduction
    • Vascular and Pigmented Lesion Removal
    • Others

By End Use

  • Hospitals
  • Clinics
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Dermatology Diagnostic Devices And Therapeutics Market 

5.1. COVID-19 Landscape: Dermatology Diagnostic Devices And Therapeutics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Dermatology Diagnostic Devices And Therapeutics Market, By Diagnostic Devices

8.1. Dermatology Diagnostic Devices And Therapeutics Market, by Diagnostic Devices, 2022-2030

8.1.1 Dermatoscopes

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Microscopes and Trichoscopes

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Imaging Equipment

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Dermatology Diagnostic Devices And Therapeutics Market, By Application Class

9.1. Dermatology Diagnostic Devices And Therapeutics Market, by Application Class, 2022-2030

9.1.1. Diagnostic Devices

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Treatment Devices

Chapter 10. Global Dermatology Diagnostic Devices And Therapeutics Market, By End Use 

10.1. Dermatology Diagnostic Devices And Therapeutics Market, by End Use, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Clinics

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

Chapter 11. Global Dermatology Diagnostic Devices And Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.1.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.1.3. Market Revenue and Forecast, by End Use (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End Use (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End Use (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.2.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.2.3. Market Revenue and Forecast, by End Use (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End Use (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End Use (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End Use (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End Use (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.3.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.3.3. Market Revenue and Forecast, by End Use (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End Use (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End Use (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End Use (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End Use (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.4.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.4.3. Market Revenue and Forecast, by End Use (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End Use (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End Use (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End Use (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End Use (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.5.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.5.3. Market Revenue and Forecast, by End Use (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End Use (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Diagnostic Devices (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application Class (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End Use (2017-2030)

Chapter 12. Company Profiles

12.1. Canfield Scientific, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis International AG

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Valeant Pharmaceuticals International, Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. gfa-Gevaert N.V.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Galderma S.A.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Michelson Diagnostics Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Cutera, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Astellas Pharma, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Genentech

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. GlaxoSmithKline plc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com